FeesSafety
Pluang+

Twin Disc Q1 sales rise 10.9% with strong defense demand and $191M backlog

Company Fundamentals
04 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Twin Disc Q1 sales rise 10.9% with strong defense demand and $191M backlog

Twin Disc reported a 10.9% year-over-year sales increase to $88.7 million in Q1 2027, driven by strong demand in defense, marine, and industrial sectors. The company achieved a stable gross margin of 28.7%, net income of $3.4 million, and a 62.6% rise in EBITDA to $7.7 million. A robust $190.6 million six-month backlog, including new defense orders from U.S. and European customers, signals continued growth. Twin Disc plans to invest in expanding manufacturing and European presence while maintaining financial discipline to support long-term goals.

Twin Disc's first quarter results show a 10.9% year-over-year sales increase to $88.7 million, highlighting strong demand in defense, marine, and industrial sectors. For readers following Industrials, here is Pluang's market snapshot as of Nov 04, 2026 19:02 WIB: out of 135 priced US Industrials stocks, 82 rose and 45 fell. Notable movers include FIX at USD 1,199.58 with a 6.66% drop and 98% sell order activity, GEO at USD 26.30 down 6.31% with a balanced buy/sell split, and VRT at USD 221.30 down 6.22% with nearly even buy and sell orders.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
27 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
27 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
27 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
27 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
27 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App